Prevalence and risk of thrombophilia defects in vascular patients

European Journal of Vascular and Endovascular Surgery

Volumn 28, Issue 2, 2004, Pages 124-131

  Vig, Stella ^a   Chitolie, A ^a   Sleight, S ^a   Bevan, D ^a   Dormandy, J ^a   Thompson, M M ^a   Halliday, A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Peripheral arterial disease and risk; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; WARFARIN;

APLASTIC ANEMIA; ATHEROSCLEROSIS; BLEEDING; CALCULATION; CLAUDICATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; PATIENT CARE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; THROMBOPHILIA; THROMBOSIS; TREATMENT FAILURE;

ADULT; ANEURYSM; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERY DISEASES; HUMANS; PERIPHERAL VASCULAR DISEASES; PREVALENCE; PROTEIN C DEFICIENCY; PROTHROMBIN; THROMBOPHILIA;

EID: 3242793632     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2004.03.027     Document Type: Review

References (34)

1. Burns P.J. Mosquera D.A. Bradbury A.W. Prevalence and significance of thrombophilia in peripheral arterial disease Eur J Vasc Endovasc Surg 22 2001 98-106
2. Alving B.M. The hypercoagulable states Hosp Pract 1993 109-121
3. Greengard J.S. Sun X. Xu X. et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va Lancet 343 1994 1362
4. Ridker P.M. Hennekens C.H. Lindpainter K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men N Engl J Med 332 1995 912-917
5. Arruda V.R. Annichino-Bizzacchi J.M. Goncalves M.S. Costa F.F. Prevalence of the prothrombin gene variant (nt20110A) in venous thrombosis and arterial disease Thromb Haemost 78 1997 1430-1433
6. O'Grady H. Kelly C. Bouchier-Hayes D. Leahy A. Homocysteine and occlusive arterial disease Br J Surg 89 7 2002 838-844
7. Ray S.A. Rowley M.R. Loh A. et al. Hypercoagulable states in patients with leg ischaemia BJS 81 1994 811-814
8. Valentine R.J. Kaplan H.S. Green R. et al. Lipoprotein (a), homocysteine and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective controlled analysis J Vasc Surg 23 1996 53-63
9. Eldrup-Jorgensen J. Preston-Flanigan D. Brace L. et al. Hypercoagulable states and lower limb ischaemia in young adults J Vasc Surg 9 1989 334-341
10. Aronson D.C. Ruys T. van Bockel J.H. et al. A prospective survey of the risk factors in young adults with arterial occlusive disease Eur J Vasc Surg 3 1989 227-232
11. Levy P.J. Gonszalez F. Hornung C.A. et al. A prospective evaluation of the atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity disease J Vasc Surg 23 1996 36-45
12. Flinn W.R. McDaniel M.D. Yao J.S.T. et al. Antithrombin III deficiency as a reflection of dynamic protein metabolism in patients undergoing vascular reconstruction J Vasc Surg 1 1984 888-895
13. Donaldson M.C. Weinberg D.S. Belkin M. et al. Screening for hypercoagulable states in vascular surgical practice J Vasc Surg 11 1990 825-831
14. Eason J.D. Mills J.L. Beckett W.C. Hypercoagulable states in arterial thromboembolism Surg Gynecol Obstets 174 1992 211-215
15. Taylor L.M. Chitwood R.W. Dalman R.L. et al. Antiphospholipid antibodies in vascular surgery patients: a cross sectional study Ann Surg 220 4 1994 544-551
16. Ouriel K. Green R.M. DeWeese J.A. Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease J Vasc Surg 23 1996 46-57
17. Sampram E.S.K. Lindblad B. The impact of Factor V Mutation on the risk of occlusion in patients undergoing peripheral vascular reconstructions Eur J Vasc Endovasc Surg 22 2001 134-138
18. Lee R.W. Taylor L.M. Landry G.J. et al. Prospective comparison of infrainguinal bypass grafting in patients with and without Antiphospholipid antibodies J Vasc Surg 24 1996 524-533
19. Evans S.M. Brittenden J. Adam D.J. et al. Vascular Surgical Society of Great Britain and Ireland; prevalence and significance of thrombophilia in patients with intermittent claudication Br J Surg 86 1999 702-703
20. Lam E.Y. Taylor L.M. Landry G.J. et al. Relationship between Antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower limb bypass operations J Vasc Surg 33 2001 976-982
21. Morton K.E. Gavaghan T.P. Krilis S.A. et al. Coronary artery bypass graft failure-an autoimmune phenomenon? Lancet 2 1986 1353-1357
22. Hamsten A. Norberg R. Bjorkholm M. et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events Lancet 1 1986 113-115
23. Kittner S.J. Gorelick P.B. Antiphospholipid antibodies and stroke: an epidemiological perspective Stroke 23 1992 I-19-I-22
24. Hess D.C. Stroke associated with Antiphospholipid antibodies Stroke 23 1992 I-23-I-28
25. Gorog P. Ridler C.D. Rees G.M. et al. Evidence against hypercoagulability in coronary artery disease Thromb Res 79 1995 377-385
26. Collins G. Heymann R.L. Zajtchuk R. Hypercoagulability in patients with peripheral vascular disease Am J Surg 130 1975 2-6
27. Ray S.A. Rowley M.R. Bevan D.H. et al. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction Eur J Vasc Endovasc Surg 13 1997 363-370
28. Nielsen T.G. Nordestgaard B.G. Von Jessen F. et al. Antibodies to cardiolipin may increase the risk of failure of peripheral vein bypasses Eur J Vasc Endovasc Surg 14 1997 177-184
29. Curi M.A. Skelly C.L. Baldwin Z.A. et al. Long term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability J Vasc Surg 37 2003 301-306
30. Scafer A.I. The hypercoagulable states Ann Int Med 102 1985 814-828
31. Peripheral Arterial Diseases Antiplatelet Consensus Group Antiplatelet therapy in peripheral arterial disease. Consensus statement Eur J Vasc Endovasc Surg 26 2003 1-16
32. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients BMJ 324 2002 71-86
33. Antiplatelet Trialists' Collaboration Secondary prevention of vascular disease by prolonged antiplatelet treatment BMJ 296 1988 320-331
34. Schusshaim A.E. Fuster V. Thrombosis, antithrombotic agents and the antithrombotic approach in cardiac disease Prog cardiovasc Dis 40 3 1997 205-238